Novartis AG NVS reported after the close today, November 3rd The New England Journal of Medicine published a study which found patients taking Afinitor tablets saw a decrease in the size of their subependymal giant cell astrocytoma. Astrocytoma's are a benign brain tumor associated with TB 1 and 2.
The company stated during a presentation at the 46th annual American Society of Clinical Oncology annual meeting this is the first study to show a beneficial use of the drug in patients.
Day's Range: 57.90 - 58.62
52wk Range: 43.48 - 60.07
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in